Pharsight

Gelnique 3% patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7029694 ALLERGAN Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US7179483 ALLERGAN Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US8241662 ALLERGAN Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Apr, 2020

(4 years ago)

US7198801 ALLERGAN Formulations for transdermal or transmucosal application
Jun, 2022

(1 year, 11 months ago)

Gelnique 3% is owned by Allergan.

Gelnique 3% contains Oxybutynin.

Gelnique 3% has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Gelnique 3% are:

  • US7029694
  • US7179483
  • US8241662
  • US7198801

Gelnique 3% was authorised for market use on 07 December, 2011.

Gelnique 3% is available in gel, metered;transdermal dosage forms.

Gelnique 3% can be used as treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.

The generics of Gelnique 3% are possible to be released after 25 June, 2022.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 07, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using OXYBUTYNIN ingredient

Market Authorisation Date:

07 December, 2011

Treatment:

Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence

Dosage:

GEL, METERED;TRANSDERMAL

More Information on Dosage

GELNIQUE 3% family patents

Family Patents